• TRR179 Podcast

    Hepcludex 2.0

    After about 5 years of Hepcludex it´s time to give a follow up on the experiences with the drug. In this episode we talk to the inventor of bulvertide, S. Urban (project leader in our TRR179) and a clinician expert (P. Lampertico from Milan).

    We will refer to the following questions:

    Which patients benefit from bulevirtide? What about HCC and decomp. cirrhosis?

    Do we need interferon for best efficacy? Are the supply chains of interferon a problem?

    What do we do with treatment failures? When is someone a treatment failure?

    What else is there beyond bulevirtide?

    What are the prospects for bulevirtide/entry inhibition in HBV monoinfection?

    TRR179 about „Attenuated effector T cells and chronic HBV infection“

    The authors are refering about the latest paper „Heim, K., Sagar, Sogukpinar, Ö. Sian Llewellyn-Lacey, David A. Price, Florian Emmerich, Anke R. M. Kraft, Markus Cornberg, Sophie Kielbassa, Percy Knolle, Dirk Wohlleber, Bertram Bengsch, Tobias Boettler, Christoph Neumann-Haefelin, Robert Thimme, Maike Hofmann. Attenuated effector T cells are linked to control of chronic HBV infection. Nat Immunol 25, 1650–1662 (2024). https://doi.org/10.1038/s41590-024-01928-4

    TRR179 and technologies

    In todays episode we learn about one of our central and service projects, which serves all research projects with their service on experimental and computational single-cell analysis with high spatial resolution.

    Career Development – Industry

    In this episode we interview our guests, the two TRR graduates Oliver Grünvogel and Julija Miller together with Peter Wimmer as a successful pharmaceutical manager to get insights about career as researcher in industry.